GlassScriptPhysician profile
Thomas Kelly
NPI 1285730986
$1,872.11
in general payments reported to CMS, 2019-2025
15 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $249 · 2021: $64.91 · 2022: $486 · 2023: $238 · 2024: $279 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $469.85 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $323.74 | 2022-2025 | Miebo, Xiidra |
| Alcon Vision LLC | $186.37 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $153.76 | 2019-2025 | |
| Sight Sciences, INC. | $152.53 | 2022 | |
| Dompe US, INC. | $147.21 | 2023-2024 | Oxervate |
| Abb Con-Cise Optical Group LLC | $98.55 | 2019-2024 | Contact Lens, Spectacle Lenses |
| Ivantis, INC | $86.08 | 2019-2021 | |
| Shire North American Group INC | $81.21 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $45.65 | 2024-2025 | Xdemvy |
| Coopervision INC. | $33.00 | 2024-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $27.72 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.09 | 2019 | |
| Biotissue Holdings INC. | $23.07 | 2022 | |
| Abbvie INC. | $19.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.